A study to evaluate the safety of incobotulinum toxin A (Xeomin) in children with cerebral palsy and muscle spasticity

Trial Profile

A study to evaluate the safety of incobotulinum toxin A (Xeomin) in children with cerebral palsy and muscle spasticity

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Cerebral palsy; Muscle spasticity
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top